News Nodality loses leader to NEA as medical diagnostics model morphs – San Francisco Business Times Growing diagnostic test developer Nodality Inc. is losing its first CEO, but the venture capital…Super UserApril 26, 2012
News Zyngenia, Inc. Recruits David Parkinson, M.D., as Board Member, Clinical Advisory Board Head, and Interim Chief Medical Officer Zyngenia, Inc., a biopharmaceutical company developing Zybodies(TM), next-generation multi-specific antibody-based drugs in oncology and immunology,…Super UserApril 25, 2012
News University of Maryland BioPark Announces MedImmune’s Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park BALTIMORE, MARYLAND, April 24, 2012 – The University of Maryland BioPark announced today thatBahija Jallal,…Super UserApril 25, 2012
News Human Genome Sciences cuts losses – Washington Business Journal Rockville-based Human Genome Sciences Inc., which last week rejected an unsolicited $2.6 billion acquisition offer…Super UserApril 25, 2012
News Maryland 12th in Venture Capital Dollars in First Quarter Venture capital dollars flowing to Maryland companies were down almost 30 percent last quarter compared…Super UserApril 25, 2012
News Maryland Establishes New Tech Transfer Fund The state and five universities are spending upwards of $5.8 million to help startups move from…Super UserApril 24, 2012
News Genome entrepreneurs say their data will help you live longer | VentureBeat The cost of sequencing the human genome continues to fall, reaching a low of $1,000…Super UserApril 23, 2012
News Supernus Pharmaceuticals readies D.C. region’s first biotech IPO since 2007 – Washington Business Journal Supernus Pharmaceuticals Inc. is slated to go public this week, more than a year after…Super UserApril 23, 2012
News Nabi Biopharmaceuticals to merge with Australian company – Baltimore Business Journal Nabi Biopharmaceuticals, which began exploring strategic alternatives after failed late-stage clinical trials of its experimental…Super UserApril 23, 2012
News What Are the Hottest Targets in Biotech Today? | Xconomy Hardly anybody wants new drugs that act like a sledgehammer, bashing diseased and healthy cells like…Super UserApril 23, 2012